Patents by Inventor Gerard M. McGeehan

Gerard M. McGeehan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of the menin-MLL interaction
    Patent number: 11919901
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: March 5, 2024
    Assignees: Syndax Pharmaceuticals, Inc., Vitae Pharmaceuticals, LLC
    Inventors: Gerard M. McGeehan, William H. Miller, Nicholas Paul Camp, Salvacion Cacatian, Santosh S. Kulkarni, Swapan Kumar Samanta, Virsinha Venkat Reddy
  • COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230165858
    Abstract: The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 7, 2021
    Publication date: June 1, 2023
    Inventors: Gerard M. MCGEEHAN, Peter ORDENTLICH, Galit ROSEN, Steven A. SMITH
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20230021684
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: May 13, 2022
    Publication date: January 26, 2023
    Inventors: Gerard M. MCGEEHAN, William H. MILLER, Nicholas Paul CAMP, Salvacion CACATIAN, Santosh S. KULKARNI, Swapan Kumar SAMANTA, Virsinha Venkat REDDY
  • Therapeutic uses of tri-aryl acid derivatives
    Patent number: 7005440
    Abstract: The use of triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 28, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley, Richard F. Labaudiniere, Litao Zhang, Robert D. Groneberg, Daniel G. McGarry, Thomas J. Caulfield, Anne Minnich, Mark Bobko, Robert Morris
  • Fluorophenyl resin compounds
    Patent number: 6639023
    Abstract: This invention is directed to a fluorophenyl resin compound, to methods of its preparation; and to its use in the solid phase synthesis of amides, peptides, hydroxamic acids, amines, urethanes, carbonates carbamates, sulfonamides and &agr;-substituted carbonyl compounds.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: October 28, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Joseph M. Salvino, Robert D. Groneberg, John E. Airey, Gregory B. Poli, Gerard M. McGeehan, Richard F. Labaudiniere, François-Frédéric Clerc, Daniel Noël André Bezard
  • Therapeutic uses of di-aryl acid derivatives
    Patent number: 6635655
    Abstract: The use of diaryl acid derivatives of formula (I) or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: October 21, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley, Richard F. Labaudiniere, Litao Zhang, Robert D. Groneberg, Daniel G. McGarry, Thomas J. Caulfield, Anne Minnich, Mark Bobko
  • Therapeutic uses of quinoline derivatives
    Patent number: 6376512
    Abstract: A method for mediating the activity of PPAR-&ggr; receptor comprising contacting said PPAR-&ggr; receptor with a compound of formula I defined herein. Also disclosed is the treatment of a patient suffering from a physiological disorder capable of being modulated by a compound of formula I having PPAR-&ggr; ligand binding activity, comprising administering to the patient a pharmaceutically acceptable amount of the compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: April 23, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley
  • Therapeutic uses of di-aryl acid derivatives
    Patent number: RE40558
    Abstract: The use of diaryl acid derivatives of formula (I) or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: October 28, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley, Richard F. Labaudiniere, Litao Zhang, Robert D. Groneberg, Daniel G. McGarry, Thomas J. Caulfield, Anne Minnich, Mark Bobko